NextGen Sciences Launches Multiplex Protein Plasma Biomarker Assays for Lung and Prostate Cancer

Share Article

NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its plasmalung27 and plasmaprostate21 multiplex protein assays, targeting lung and prostate cancer biomarker discovery and qualification. The assays simultaneously measure 27 and 21 human plasma proteins that are believed to have potential as biomarkers in lung cancer and prostate cancer respectively.

NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its plasmalung27 and plasmaprostate21 multiplex protein assays, targeting lung and prostate cancer biomarker discovery and qualification. The assays simultaneously measure 27 and 21 human plasma proteins that are believed to have potential as biomarkers in lung cancer and prostate cancer respectively.

Klaus Rosenau, Chairman and CEO of NextGen Group, commented, ‘The release of the plasmalung27 and plasmaprostate21 is the next step in our on-going plans to release oncology and CNS disease focused, multiplex assays for biomarker discovery and qualification. It is core to our development strategy that we develop assays with protein content that is relevant to the therapeutic markets we are striving to address. To ensure we continually deliver the high-quality assays that pharmaceutical, biotechnology and diagnostics companies need to inform their decision-making processes, NextGen Sciences is currently planning more such products in the near future.’

NextGen’s assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. NextGen expects to develop further oncology and CNS disease-focused assay panels, both as proprietary products and with other companies, through partnerships and collaborations.

For more information:

NextGen Group
Klaus Rosenau, Chairman and CEO
klaus.rosenau(at)nextgensciences(dot)com
+49 160 551 6756

Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000

Notes to Public

NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasingly important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, http://www.marketsandmarkets.com) playing an important role. NextGen Sciences’ products include discovery of new biomarkers and targets, assay development, and biomarker qualification. For more information visit http://www.nextgensciences.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Klaus Rosenau, Chairman and CEO
NextGen Group
+49 160 551 6756
Email >

Jonathan Wright, Nicola Marrin
Seymour Pierce
+44 (0) 20 7107 8000
Visit website